Key facts
- Synthesize Bio’s last known valuation is $30.0M (Sep 2025).
- It has raised $10.0M; the latest was Seed Round ($10.0M) in Sep 2025.
- Notable investors include Madrona Venture Group, AI2 Incubator, Point Field Partners, Inner Loop Capital, Sahsen Ventures.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Synthesize Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Synthesize Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Synthesize Bio
Developer of a biomedical discovery software designed to accelerate the pace of data generation, analysis, and hypothesis testing. The company's software uses AI to reduce data collection and analysis from months to minutes for a fraction of the cost in time, personnel, and materials, enabling scientists and researchers in the biotech and pharmaceutical sectors to derive valuable insights for innovation and discovery in genomics.
- Sector
- Information Technology
- HQ
- Seattle, WA, United States
- Founded
- 2023
- Employees
- 16
- Website
- synthesize.bio/
- Ownership
- Privately Held (backing)
Synthesize Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Synthesize Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Synthesize Bio in its N-PORT filings yet. We sweep new filings monthly.